-- GeneDx (WGS) reported Monday Q1 adjusted loss of $0.28 per diluted share, swinging from an adjusted earnings of $0.31 a year earlier.
Analysts polled by FactSet expected loss of $0.02.
Revenue for the quarter ended March 31 was $102.3 million, up from $87.1 million a year earlier.
Analysts surveyed by FactSet expected $112.5 million.
For Q2, the company expects revenue of $110 million to $112 million. Analysts expect $130.3 million.
The company now expects 2026 revenue of $475 million to $490 million, down from $540 million to $555 million expected earlier. Analysts expect $550.0 million.
Shares of the company were down over 45% during after-hours activity.